Invivyd develops monoclonal antibody medicines designed to protect against serious viral infectious diseases, beginning with COVID-19. Using its INVYMAB platform that integrates viral surveillance, predictive modeling, and antibody engineering, the company creates therapies intended to remain effective as viruses evolve. Its lead product PEMGARDA received U.S. FDA emergency use authorization for pre-exposure prophylaxis in certain immunocompromised patients, and the company is advancing additional candidates including for RSV.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 11.3 | — | -16.3 | — |
| Q2 2025 | 11.8 | — | -14.7 | — |
| Q3 2025 | 13.1 | — | -10.5 | — |
| Q4 2025 | 17.2 | — | -11.1 | — |
| Q1 2026 | 13.7 | 21.6% | -41.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: X3 Acquisition Corp. Ltd. (XCBE), A2Z Cust2Mate Solutions Corp. (AZ), Cartesian Therapeutics, Inc. (RNAC), QNB Corp. (QNBC), Runway Growth Finance Corp. (RWAY), Snow Rothschild Acquisition Corp (ISNR)